Amifampridine

Amifampridine Overview

Amifampridine (chemically known as 3,4-diaminopyridine or 3,4-DAP; chemical formula C5H7N3) is a quaternary organic compound belonging to the aminopyridines class within the organoheterocyclic superclass. Structurally, it consists of a six-membered pyridine ring substituted with two primary amino groups at the 3- and 4-positions.

In clinical neurology, neuromuscular medicine, and neuropharmacology, Amifampridine functions as a first-line symptomatic treatment for neuromuscular junction disorders (ATC code N07XX05). Formulated as Amifampridine phosphate (a stable salt) in 10 mg oral scored tablets (marketed under the brand names Firdapse and historically Ruzurgi), it is indicated for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adult and pediatric patients. Approved by the US FDA in November 2018 (Firdapse) and by the European Medicines Agency (EMA) in 2009, Amifampridine restores neuromuscular transmission by enhancing presynaptic acetylcholine release.

What Is Amifampridine and How Does It Work?

Amifampridine acts primarily through presynaptic voltage-gated potassium channel blockade at the neuromuscular junction.

Its primary chemical, physiological, and cellular mechanisms include:

• Selective Potassium Channel Blockade: Amifampridine selectively blocks presynaptic fast voltage-gated potassium channels (specifically Kv1.1 / KCNA1) on motor nerve terminals.
• Prolongation of Nerve Terminal Depolarization: Blocking potassium efflux delays presynaptic membrane repolarization, significantly extending the duration of the nerve terminal action potential.
• Augmented Intracellular Calcium Influx: Prolonged action potentials keep presynaptic P/Q-type voltage-gated calcium channels open for an extended duration. This increases the influx of extracellular calcium ions (Ca2+) into the presynaptic nerve terminal.
• Enhancement of Quantal Acetylcholine Release: Elevated presynaptic intracellular calcium concentration triggers vesicular exocytosis, promoting the quantal release of acetylcholine (ACh) into the synaptic cleft.
• CMAP Restorations & Muscle Strength: Increased acetylcholine concentration in the synaptic cleft overcomes autoimmune blockade of presynaptic calcium channels characteristic of LEMS. This restores miniature endplate potential frequency, increases muscle fiber activation, and elevates compound muscle action potential (CMAP) amplitudes, improving proximal muscle strength and autonomic function.

Is Amifampridine FDA Approved?

Yes, Amifampridine is approved by the US FDA. It received its initial FDA approval on November 28, 2018 under NDA 209229 (Firdapse, amifampridine phosphate 10 mg oral scored tablets by Catalyst Pharmaceuticals) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. The FDA subsequently expanded Firdapse’s approval to include pediatric patients aged 6 years and older.

What Is Amifampridine Used For?

• Symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and pediatric patients (6 years of age and older).
• Non-immune symptomatic control of LEMS-associated proximal muscle weakness, depressed tendon reflexes, fatigue, and autonomic dysfunction (e.g., dry mouth, erectile dysfunction).

Before Taking Amifampridine: Contraindications & Precautions

Screen for a documented history of epilepsy or seizure disorders, as Amifampridine causes dose-dependent seizure threshold reduction. Contraindicated in patients with severe hypersensitivity to aminopyridines or 4-aminopyridine, and those taking concurrent medications that lower the seizure threshold. Slow NAT2 acetylators experience significantly increased drug exposure and higher rates of paresthesias, nausea, and seizures. Use during pregnancy and lactation only if potential benefits outweigh fetal and infant risks.

Who Should Not Take Amifampridine?

• Individuals with a documented history of seizures or epilepsy (Amifampridine lowers the seizure threshold in a dose-dependent manner).
• Patients with known severe hypersensitivity to Amifampridine, 4-aminopyridine (dalfampridine), aminopyridines, or formulation excipients.
• Patients taking concurrent medications that lower the seizure threshold or other potassium channel blockers.

Genetic Polymorphisms & NAT2 Acetylator Status

Amifampridine is cleared primarily by hepatic N-acetyltransferase 2 (NAT2) enzymes. Genetic variations in NAT2 determine an individual’s acetylator phenotype:

• Slow Acetylators: Individuals with slow NAT2 acetylator phenotypes experience significantly higher systemic drug exposure (higher Cmax​ and AUC) compared to fast acetylators.
• Increased Risk of Adverse Reactions: Slow acetylators have a higher incidence of dose-dependent adverse reactions, including paresthesias, nausea, headaches, and potential seizures. Dosage titrations must proceed slowly in known or suspected slow acetylators.

Amifampridine, Pregnancy & Lactation

Amifampridine should be used during pregnancy only if the potential benefit justifies potential risks to the fetus. Animal reproduction studies at high doses have demonstrated developmental toxicity and embryo-fetal mortality. It is unknown whether Amifampridine is excreted in human breast milk; nursing mothers should weigh the clinical need for therapy against potential risks to the infant.

Tell Your Doctor Before Taking Amifampridine

Inform your neurologist or physician if you have a history of seizures, brain lesions, kidney disease, liver impairment, or cardiac arrhythmias (QTc prolongation).

Amifampridine Dosage & Administration

Standard adult LEMS starting dose is 15 mg to 30 mg daily, divided into 3 or 4 doses per day. Titrate upwards by 5 mg daily every 3 to 4 days based on clinical response, to a maximum single dose of 20 mg and a maximum total daily dose of 80 mg. Pediatric patients (6 years and older) weighing 45 kg or more start at 15 mg to 30 mg daily (max 80 mg daily); those under 45 kg start at 7.5 mg to 15 mg daily (max 40 mg daily). Initiate at 15 mg daily in renal or hepatic impairment.

Standard Dosing Guidelines

• Adult LEMS Dosing (Firdapse):

• Starting Dosage: 15 mg to 30 mg daily, divided into 3 or 4 doses per day (e.g., 5 mg to 10 mg 3 or 4 times daily).
• Titration: Increase dosage by 5 mg daily every 3 to 4 days based on clinical response and tolerability.
• Maximum Single Dose: 20 mg per single dose.
• Maximum Total Daily Dose: 80 mg daily.
• Pediatric LEMS Dosing (6 Years and Older):

• Weighing 45 kg or More: Start at 15 mg to 30 mg daily in divided doses; titrate up to a maximum of 80 mg daily (max 20 mg per single dose).
• Weighing Less Than 45 kg: Start at 7.5 mg to 15 mg daily in divided doses; titrate up to a maximum of 40 mg daily (max 10 mg per single dose).

How Amifampridine Is Administered

• Take oral tablets in divided doses 3 to 4 times daily at evenly spaced intervals throughout waking hours.
• Can be taken with or without food.
• Scored 10 mg tablets can be split along the score line to achieve 5 mg increments.

Amifampridine Clinical Efficacy & Research

Randomized, double-blind, placebo-controlled Phase 3 clinical trials in adult LEMS patients established that Amifampridine produces significant improvements in quantitative neuromuscular function. Treatment with Amifampridine yielded statistically significant improvements in Quantitative Myasthenia Gravis (QMG) scores and Subject Global Impression (SGI) scores compared to placebo withdrawal.

Amifampridine Side Effects & Safety Profile

Acts via selective presynaptic Kv1.1 voltage-gated potassium channel blockade, prolonging nerve terminal depolarization to increase calcium influx and acetylcholine exocytosis. Common side effects include peripheral and perioral paresthesias, headache, dizziness, nausea, abdominal pain, and muscle spasms.

Safety Warnings

Amifampridine carries important safety warnings regarding Dose-Dependent Seizures, Hypersensitivity Reactions, and NAT2 Slow Acetylator Toxicity.

Common Side Effects

• Neurological: Paresthesias (tingling or numbness around the mouth, face, hands, and feet), headache, dizziness, and hypoesthesia.
• Gastrointestinal: Nausea, abdominal pain, diarrhea, and dyspepsia.
• Musculoskeletal: Muscle spasms and back pain.
• Autonomic / General: Upper respiratory tract infections and influenza-like symptoms.

Serious Adverse Events

• Seizures & Convulsions: Dose-dependent central nervous system excitation and tonic-clonic seizures, occurring most frequently at high doses or in patients with underlying seizure risks or slow NAT2 clearance.
• Severe Hypersensitivity & Anaphylaxis: Facial angioedema, urticaria, bronchospasm, and acute allergic reactions.
• Cardiac Arrhythmias & QTc Prolongation: Potential prolongation of cardiac repolarization when co-administered with QTc-prolonging drugs.

Managing Side Effects

Paresthesias are usually mild, transient, and dose-related. If a seizure occurs, discontinue Amifampridine immediately and re-evaluate the patient’s neurological status before considering lower doses.

Amifampridine Drug Interactions & What to Avoid

Co-administration with seizure-threshold-lowering agents (bupropion, tramadol, theophylline, antipsychotics) or other aminopyridines (dalfampridine) is strictly contraindicated due to severe central nervous system toxicity and seizure risks. Concomitant use with acetylcholinesterase inhibitors (pyridostigmine) may produce additive cholinergic side effects. Avoid alcohol, as it lowers the seizure threshold and exacerbates CNS toxicity.

Drug-Drug Interactions

• Seizure-Threshold Lowering Medications (e.g., Bupropion, Tramadol, Antipsychotics, Theophylline): Co-administration significantly increases the risk of grand mal seizures; concurrent use should be avoided or monitored closely.
• Potassium Channel Blockers (e.g., Dalfampridine / 4-Aminopyridine): Concurrent use with other aminopyridine potassium channel blockers increases the risk of severe central nervous system toxicity and seizures; combination is contraindicated.
• Cholinergic Agents / Acetylcholinesterase Inhibitors (e.g., Pyridostigmine): May produce additive cholinergic effects (diarrhea, muscle twitching, excessive salivation).
• OCT2 / OAT3 Inhibitors: Amifampridine is a substrate of renal transporters; co-administration may alter renal elimination.

Food & Alcohol

Avoid alcohol consumption, as alcohol may lower the seizure threshold and exacerbate central nervous system side effects.

Amifampridine Overdose, Emergency & Clearance

Absorbed rapidly with peak plasma levels in 0.6 to 1 hour, undergoing hepatic NAT2 N-acetylation and rapid renal clearance with an elimination half-life of 1.8 to 2.5 hours (3 to 5 hours in slow acetylators). Overdose triggers acute central nervous system excitation, grand mal seizures, status epilepticus, severe vomiting, and cardiac arrhythmias requiring immediate drug cessation, airway support, IV benzodiazepines, and ICU management. Store tablets at 20°C to 25°C away from heat and moisture.

Elimination Kinetics & Overdose

Amifampridine is rapidly absorbed orally, reaching peak plasma concentrations (Cmax​) within 0.6 to 1 hour under fasting conditions. It is metabolized primarily by hepatic N-acetyltransferase 2 (NAT2) to an inactive 3-N-acetylamifampridine metabolite. Plasma protein binding is minimal (<10%). It is excreted rapidly by the kidneys (approx. 93% to 98% recovered in urine within 24 hours as metabolite and parent drug). The elimination half-life (t1/2​) ranges from 1.8 to 2.5 hours in fast acetylators, extending up to 3 to 5 hours in slow NAT2 acetylators. Acute overdose produces severe central nervous system excitation, grand mal seizures, status epilepticus, severe vomiting, cardiac arrhythmias, and paroxysmal hypertension. Treatment includes immediate drug discontinuation, airway management, IV benzodiazepines for seizures, and supportive cardiovascular care.

Storage & Handling

Store 10 mg scored tablets at controlled room temperature between 20°C and 25°C (68°F to 77°F). Protect from excessive heat, moisture, and direct light. Keep strictly out of reach of children.

Amifampridine Patient Management & Safety Protocols

Assess baseline renal function, liver enzymes, and personal or family seizure history prior to treatment initiation. Monitor clinical improvement via quantitative muscle strength scoring while evaluating for early paresthesias or seizure activity. Instruct patients never to exceed 20 mg in a single dose or 80 mg total per day.

Clinical Monitoring Checklist

• Screen for any personal or family history of seizure disorders before initiating therapy.
• Assess baseline renal function (eGFR) and liver function.
• Consider NAT2 genotype testing or phenotype assessment in patients experiencing early severe paresthesias or side effects.
• Monitor for clinical improvement in proximal muscle strength and QMG/SGI scores during dose titration.

Key Do’s and Don’ts

• Do divide daily doses into 3 to 4 small doses throughout the day.
• Do titrate doses slowly in increments of 5 mg every 3 to 4 days.
• Do report any seizure activity, severe tingling, or allergic reactions immediately.
• Do not exceed 20 mg in a single dose or 80 mg in a total daily dose.
• Do not take concurrently with other 4-aminopyridine medications.
• Do not abruptly stop taking prescribed medication without consulting your neurologist.

Frequently Asked Questions

References

• DrugBank Database – Amifampridine Profile (DB11640)
• Classyfire Database – Aminopyridines and Derivatives Chemical Taxonomy Profile
• Official FDA Prescribing Information – Firdapse (Amifampridine Phosphate Tablets)
• European Medicines Agency (EMA) – Firdapse Summary of Product Characteristics

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.